Our additional findings on the in vivo Rac1 inhibitor sensitivity in RAC1-amp melanoma and RAC1-A159V-mutated endometrial cancer, and the noted outlier EHT-1864 sensitivity (inhibitor of Rac1, Rac2, and Rac3) from the GDSC dataset both suggest that the chemical targeting of Rac1 or Rac1, 2, or 3 may be worth more attention in other cancers, such as ECAD, stomach, ALL, breast, LUAD (based on GDSC data), and endometrial cancers, as well as melanoma (based on our findings). This evidence concerns the gene RAC3 and acute lymphoblastic leukemia.